| Name | Title | Contact Details |
|---|
BioBridges is a Wellesley Hills, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Miraca Life Sciences serves more than 5,500 patients each day, providing expert pathology services in the fields of dermatopathology, breast pathology, gastroenterology, hematology/oncology and urology. Additionally, Miraca has provided health IT consulting services to hundreds of practices, helping providers with programs such as MIPS, quality reporting, Meaningful Use, security risk assessments, and HIPAA compliance. The company, previously known as Caris Diagnostics, was renamed Miraca Life Sciences in February 2012. Miraca Life Sciences is a subsidiary of Miraca Holdings Inc., one of Japan`s largest clinical diagnostics and laboratory testing service providers. As a leader in anatomic pathology, Miraca Life Sciences combines the rigor of an academic medical institution with the innovative spirit of a technology company. By working for Miraca, you will have the opportunity to contribute alongside top multidisciplinary talented professionals, who are dedicated to meeting the needs of our clients and their patients. You will work in a state-of-the-art environment with cutting-edge tools, breakthrough technologies and with world-renowned thought leaders. The company offers a forward-thinking business model seeking to make a profound difference in the quality of care for patients.
Pivot was created by Carrot Inc., a digital health company on a mission to use mobile technology, behavioral science, and clinical expertise to engage and empower millions of people to quit smoking.
DENTAL ARTS LABORATORY Inc is a Peoria, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.